Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.39 |
| ▸ | FHIT | P49789 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.37 |
| ▸ | AHCY | P23526 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADA | P00813 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20691308 | 0.92 | RNASEL (0.44) | POLBRNASELFHITBCHEENPP1 | |
| SCHEMBL24258606 | 0.88 | POLB (0.42) | POLBRNASELFHITBCHEENPP1 | |
| SCHEMBL20691300 | 0.84 | FHIT (0.38) | POLBRNASELFHITBCHEENPP1 | |
| SCHEMBL6915658 | 0.81 | BCHE (0.51) | POLBBCHEENPP1P2RY1TAS1R3 | |
| SCHEMBL22990586 | 0.81 | BCHE (0.51) | POLBBCHEENPP1P2RY1TAS1R3 | |
| SCHEMBL20225033 | 0.81 | BCHE (0.51) | POLBBCHEENPP1P2RY1TAS1R3 | |
| SCHEMBL20691398 | 0.78 | POLB (0.53) | POLBRNASELFHITENPP1P2RY1 | |
| SCHEMBL22765943 | 0.77 | POLB (0.51) | POLBFHITENPP1P2RY1TAS1R3 | |
| SCHEMBL24444145 | 0.76 | POLB (0.46) | POLBRNASELFHITENPP1P2RY1 | |
| SCHEMBL24258656 | 0.76 | TAS1R3 (0.42) | RNASELFHITBCHEP2RY1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | POLB 30/4885RNASEL 662/4885FHIT 4468/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | POLB 30/4885RNASEL 662/4885FHIT 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.